Novartis Is Largely Abandoning Ionis Heart Drug After Trial Failure

Novartis is largely abandoning development of a heart disease treatment discovered by Ionis Pharmaceuticals after the RNA-targeting candidate failed in a late-stage trial last September.

Ionis discovered the candidate, which targets RNA. Novartis had been developing it for heart disease.